Profil
Irackly Mtibelishvily worked as a Director at Argos Therapeutics, Inc. from 2016 to 2018.
He graduated from Moscow State Institute of International Relations and the University of Virginia School of Law with graduate degrees.
Anciens postes connus de Irackly Mtibelishvily
| Sociétés | Poste | Fin |
|---|---|---|
| ARGOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/11/2018 |
Formation de Irackly Mtibelishvily
| University of Virginia School of Law | Graduate Degree |
| Moscow State Institute of International Relations | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
